EGFR and non-small cell lung carcinoma: To this end, we showed that approximately 12% of EGFR-mutant NSCLC tumors exhibited high FGFR1 expression, suggesting that EGFR-TKI are driving FGFR1 in patients with primary adenomacarcinoma NSCLC.